Ajay Madan - 31 Dec 2021 Form 5 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Development Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
31 Dec 2021
Net transactions value
+$8,651
Form type
5
Filing time
04 Feb 2022, 15:26:08 UTC
Previous filing
01 Nov 2021
Next filing
09 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Other $8,651 +785 +0.43% $11.02 185,456 19 Nov 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).